M-A Perales

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Enhanced responses to tumor immunization following total body irradiation are time-dependent
    Adi Diab
    Swim Across America Laboratory of Tumor Immunology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 8:e82496. 2013
  2. ncbi request reprint Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    Miguel Angel Perales
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:2022-9. 2008
  3. pmc Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
    Miguel Angel Perales
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:4882-91. 2012
  4. ncbi request reprint DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
  5. ncbi request reprint Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease
    M A Perales
    Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 40:481-6. 2007
  6. pmc Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT
    M A Perales
    Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bone Marrow Transplant 45:1408-16. 2010
  7. ncbi request reprint Melanoma vaccines
    Miguel Angel Perales
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford I Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Cancer Invest 20:1012-26. 2002
  8. ncbi request reprint Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains
    Cristina R Ferrone
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, Weill Medical and Graduate Schools of Cornell University, New York, NY 10021, USA
    Clin Cancer Res 12:5511-9. 2006
  9. ncbi request reprint Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles
    Stacie M Goldberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8114-21. 2005
  10. ncbi request reprint CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004

Research Grants

  1. Optimizing T cell Immunity to Cancer Vaccines
    Miguel Angel Perales; Fiscal Year: 2006

Collaborators

Detail Information

Publications19

  1. pmc Enhanced responses to tumor immunization following total body irradiation are time-dependent
    Adi Diab
    Swim Across America Laboratory of Tumor Immunology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 8:e82496. 2013
    ..Clinical strategies using these approaches must therefore optimize such parameters, as the correct timing of infusion and vaccination may mean the difference between an ineffective treatment and successful tumor eradication. ..
  2. ncbi request reprint Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    Miguel Angel Perales
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:2022-9. 2008
    ..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant...
  3. pmc Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
    Miguel Angel Perales
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:4882-91. 2012
    ..Our results indicate that r-hIL-7 can enhance immune recovery after a T cell-depleted allo-HSCT without causing significant GVHD or other serious toxicity (www.clinicaltrials.gov; NCT00684008)...
  4. ncbi request reprint DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
    ..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
  5. ncbi request reprint Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease
    M A Perales
    Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 40:481-6. 2007
    ..Careful patient selection and aggressive prophylaxis against viral and fungal infections are recommended...
  6. pmc Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT
    M A Perales
    Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bone Marrow Transplant 45:1408-16. 2010
    ..Furthermore, the sAAIPI can predict outcomes and may be used to select the most appropriate patients for this type of transplant...
  7. ncbi request reprint Melanoma vaccines
    Miguel Angel Perales
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford I Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Cancer Invest 20:1012-26. 2002
    ..In this review, we will discuss strategies to induce active immunity against melanoma...
  8. ncbi request reprint Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains
    Cristina R Ferrone
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, Weill Medical and Graduate Schools of Cornell University, New York, NY 10021, USA
    Clin Cancer Res 12:5511-9. 2006
    ..We compared DNA adjuvants for their ability to enhance immunity against a poorly immunogenic self-antigen expressed by cancer...
  9. ncbi request reprint Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles
    Stacie M Goldberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8114-21. 2005
    ..The purpose of this study was to compare viral and plasmid DNA in combination vaccination strategies in the context of a tumor antigen...
  10. ncbi request reprint CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004
    ..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration...
  11. pmc Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants
    Dana Jaffe
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 108:2470-5. 2006
    ....
  12. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
    ..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen...
  13. ncbi request reprint Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Trudy N Small
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:235-44. 2007
    ..For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies...
  14. pmc Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity
    Adam D Cohen
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:4904-12. 2006
    ..Finally, this effect on vaccine-induced CD8(+) T-cell responses was partially independent of CD4(+) T cells (both helper and regulatory), consistent with a direct costimulatory effect on the effector CD8(+) cells themselves...
  15. ncbi request reprint Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation
    Johannes L Zakrzewski
    Department of Medicine, Zuckerman Research Center 1404, Mailbox 111, New York, New York 10021, USA
    Nat Med 12:1039-47. 2006
    ..We conclude that the adoptive transfer of OP9-DL1-derived T-cell precursors markedly enhances T-cell reconstitution after transplantation, resulting in GVT activity without GVHD...
  16. ncbi request reprint Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines
    David Z Chang
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hematology 9:207-15. 2004
    ..GM-CSF is an attractive vaccine adjuvant because of its immune modulation effects and low toxicity profile. The results in animal models have been confirmed in pilot clinical trials and several clinical trials are currently ongoing...
  17. ncbi request reprint GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines
    Miguel Angel Perales
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cytokines Cell Mol Ther 7:125-33. 2002
    ..These results have implications for understanding early events in the immune response to DNA vaccines, and provide a basis for development of new approaches to cancer vaccines, including the use of cytokine genes as adjuvants...
  18. ncbi request reprint Strategies to overcome immune ignorance and tolerance
    Miguel Angel Perales
    Memorial Sloan Kettering Cancer Center and Weill Medical School and Graduate School of Cornell University, New York, NY 10021, USA
    Semin Cancer Biol 12:63-71. 2002
    ..Crucial to these approaches is the discovery and understanding of the molecular identity of antigens and the mechanisms involved in tumor immunity. In this review, strategies to overcome immune ignorance and tolerance are discussed...
  19. ncbi request reprint CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytes
    Miguel Angel Perales
    Ann Surg Oncol 11:881-2. 2004

Research Grants1

  1. Optimizing T cell Immunity to Cancer Vaccines
    Miguel Angel Perales; Fiscal Year: 2006
    ..This environment maximizes the potential for the principal investigator to establish a successful independent research program. ..